Phospho-MET (Tyr1003) Polyclonal Antibody, AbBy Fluor-680 Conjugated, BF680, Rabbit

Catalog Number: BSS-BS-3271R-BF680
Article Name: Phospho-MET (Tyr1003) Polyclonal Antibody, AbBy Fluor-680 Conjugated, BF680, Rabbit
Biozol Catalog Number: BSS-BS-3271R-BF680
Supplier Catalog Number: bs-3271R-BF680
Alternative Catalog Number: BSS-BS-3271R-BF680-100
Manufacturer: Bioss
Host: Rabbit
Category: Antikörper
Application: WB
Species Reactivity: Human, Rat
Conjugation: BF680
Alternative Names: Met c-Met Tyr1003, AUTS9, c met, cmet, D249, Hepatocyte growth factor receptor, Hepatocyte growth factor receptor Precursor, HGF, HGF receptor, HGF SF receptor, HGF/SF receptor, HGFR, MET, Met proto oncogene tyrosine kinase, Met proto-oncogene hepatocyte growth factor receptor, Met proto-oncogene, Met protooncogene, MET_HUMAN, Oncogene MET, Par4, Proto-oncogene c-Met, RCCP2, Renal cell carcinoma papillary 2 gene, Scatter factor receptor, SF receptor, Tyrosine-protein kinase Met.
c-Met, a member of the tyrosine kinase superfamily, is the receptor for hepatocyte growth factor, also known as scatter factor (HGF/SF). The mature c-Met protein is a disulfide-linked heterodimer with Mr=190 kDa composed of a heavily glycosylated alpha subunit that is completely extracellular in localization, and a beta subunit comprising an extracellular ligand binding domain, a single transmembrane domain, and a cytoplasmic tyrosine kinase domain. Cells expressing c-Met include epithelial cells, endothelial cells, blood cells of various types, and glomerular mesenchymal cells.HGF/SF binding to c-Met stimulates receptor dimerization and the phosphorylation of numerous residues within the receptor?????s cytoplasmic domain. Signaling proteins that are phosphorylated and/or localized in response to c-Met phosphorylation include: Grb2, Shc, Cbl, Crk, cortactin, paxillin, GAB1, PI3K, FAK, Src, Ras, ERK1 and 2, JNK, PLC gamma, AKT, and STAT3. HGF/SF stimulation of c-Met expressing cells enhances proliferation, migration, morphogenesis, and protease synthesis, characteristics that are associated with invasive cell phenotype. Many types of cancer exhibit sustained c-Met stimulation, overexpression, or mutation, including carcinomas of the colon, breast, ovary, lung, liver, prostate, thyroid, kidney, as well as melanomas and sarcomas. In addition to cancer studies, other research areas in which c-Met is under investigation include organogenesis, organ regeneration, angiogenesis and surgical wound healing.
Clonality: Polyclonal
Concentration: 1ug/ul
NCBI: 4233
Buffer: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Source: KLH conjugated synthetic phosphopeptide derived from human c-Met around the phosphorylation site of Tyr1003
Target: Phospho-MET (Tyr1003)
Application Dilute: WB(1:300-5000)